Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review
Background: Cholangiocarcinoma (CCA) is a highly aggressive malignant tumor with poor overall survival. Although the first-line standard chemotherapy (gemcitabine plus cisplatin) combined with immunotherapy has yielded positive results with survival prolongation, the efficacy remains unsatisfactory,...
Main Authors: | Sirui Tan, Jing Yu, Qiyue Huang, Nan Zhou, Xianze Xiong, Hongfeng Gou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1037646/full |
Similar Items
-
PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series
by: Sirui Tan, et al.
Published: (2022-11-01) -
Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
by: Francesco Di Costanzo, et al.
Published: (2023-01-01) -
Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
by: Ken Kamata, et al.
Published: (2023-09-01) -
Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
by: Yafan Yang, et al.
Published: (2023-03-01) -
Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
by: E. I. Borisova, et al.
Published: (2018-11-01)